An updated review on morpholine derivatives with their pharmacological actions

Chaitanya Prasad Meher; Debashis Purohit; Ashish Kumar; Raghuvendra Singh; Anubhav Dubey

doi:10.53730/ijhs.v6nS3.5983

Authors

Chaitanya Prasad Meher
chaitanyameher84@gmail.com
Assistant Professor, Department of Pharmaceutical Chemistry School of Pharmacy, Centurion University of Technology & Management, Odisha, India
Debashis Purohit Research Scholar, Department of Pharmacy, Career Point University, Kota, Rajasthan, India
Ashish Kumar Research Scholar, Department of Pharmacy, Career Point University, Kota, Rajasthan, India
Raghuvendra Singh Research Scholar, Department of Pharmacy, Career Point University, Kota, Rajasthan, India
Anubhav Dubey Assistant Professor, Department of Pharmacology, Maharana Pratap College of Pharmacy Kanpur, Uttar Pradesh, India

Keywords:

hetero cyclic compound, morpholine, disease, therapeutic agents

Abstract

The invention of newer chemical entities, which have some therapeutically worth is always a great challenge. It is no doubt that it is a lengthier process. We have several drugs in the market for treatment of wide variety of diseases. The marketed drugs available may be heterocyclic or non-heterocyclic derivatives. Always it was found that heterocyclic derivatives have wide variety of pharmacological activity. The intension of this review is to highlight one of the important heterocyclic rings i.e.: Morpholine. Several works have been done on this nucleus, which should be enlighten for more and more applicability.

Downloads

Download data is not yet available.

References

Neznamov, GG; Siuniakov, SA; Chumakov, DV; Bochkarev, VK; Seredenin, SB (2001). "Clinical study of the selective anxiolytic agent afobazol". Eksperimental'naia i Klinicheskaia Farmakologiia. 64 (2): 15–9. PMID 11548440.

Silkina, IV; Gan'shina, TC; Seredin, SB; Mirzoian, RS (2005). "Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon". Eksperimental'naia i Klinicheskaia Farmakologiia. 68 (1): 20–4. PMID 15786959.

Seredin, SB; Melkumian, DS; Val'dman, EA; Iarkova, MA; Seredina, TC; Voronin, MV; Lapitskaia, AS (2006). "Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction". Eksperimental'naia i Klinicheskaia Farmakologiia. 69 (3): 3–6. PMID 16878488

Neznamov, GG; Siuniakov, SA; Chumakov, DV; Bochkarev, VK; Seredenin, SB (2001). "Clinical study of the selective anxiolytic agent afobazol". Eksperimental 'naiai klinicheskaia farmakologiia 64 (2): 15–9.

Bergström, M; Hargreaves, RJ; Burns, HD; et al. (May 2004). "Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant". Biological Psychiatry. 55 (10): 10071012. doi:10.1016/j.biopsych.2004.02.007

Ralla R, De Wit R, Herrstedt J, Carides A, Ianus J, Guoguang-Ma J, Evans J, Horgan K (2005). "Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials". Cancer 104 (4): 864–8.

Kan JP, Steinberg R, Leclercq J, Worms P, Biziere K (April 1988). "Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro". Journal of Neurochemistry. 50 (4): 1137–44. doi:10.1111/j.1471-4159.1988.tb10584.x. PMID 3346672. S2CID 12521641.

Smaill, JB; Rewcastle, GW; Loo, JA; Greis, KD; Chan, OH; Reyner, EL; Lipka, E; Showalter, HD; et al. (2000). "Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido3,2-dpyrimidine-6-acrylamides bearing additional solubilizing functions". Journal of Medicinal Chemistry. 43 (7): 1380 97. doi:10.1021/jm990482t. PMID 10753475.

https://pubchem.ncbi.nlm.nih.gov/compound/Cobicistat#section=Drug-and-Medication-Information.

R Elion, J Gathe, B Rashbaum, and others. The Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF; Quad) Maintains a High Rate of Virologic Suppression, and Cobicistat (COBI) is an Effective Pharmacoenhancer Through 48 Weeks. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010). Boston, September 12–15, 2010.

Den Otter G, Pain control with dextromoramide (pyrrolamidolum, R 875, palfium), Ned Tijdschr Geneeskd. 1958 Aug 23;102(34):1637-41.

De Vos JW, Ufkes JG, van den Brink W, van Brussel GH, de Wolff FA (1999). "Craving patterns in methadone maintenance treatment with dextromoramide as adjuvant". Addictive Behaviors. 24 (5): 707–13. doi:10.1016/s0306-4603(98)00081-1. PMID 10574310

Mark G. Papich, Doxapram Hydrochloride, Editor(s): Mark G. Papich, Saunders Handbook of Veterinary Drugs (Fourth Edition), W.B. Saunders, 2016, Pages 269-271.

Singh, P; Dimitriou, V; Mahajan, RP; Crossley, AW (1993). "Double-blind comparison between doxapram and pethidine in the treatment of postanaesthetic shivering". British journal of anaesthesia 71 (5): 685–8.

Jun Yan (March 2012). "Pipeline for new antidepressants flowing slowly". Psychiatric News. American Psychiatric Association. 47 (5): 1b–29. doi:10.1176/pn.47.5.psychnews_47_5_1-b

Chancellor D (November 2011). "The depression market". Nature Reviews. Drug Discovery 10 (11): 809–10.

Harder A, Holden-Dye L, Walker R, Wunderlich F. Mechanisms of action of emodepside. Parasitol Res. 2005 Oct;97 Suppl 1:S1-S10. doi: 10.1007/s00436-005-1438-z. PMID: 16228263.

Willson J, Amliwala K, Harder A, Holden-Dye L, Walker RJ (2003). "The effect of the anthelmintic emodepside at the neuromuscular junction of the parasitic nematode Ascaris suum". Parasitology 126 (Pt 1): 79–86.

Rao SG (October 2009). "Current progress in the pharmacological therapy of fibromyalgia". Expert Opinion on Investigational Drugs 18 (10): 1479–93.

Keup W (June 1986). "Use, indications and distribution in different countries of the stimulant and hallucinogenic amphetamine derivatives under consideration by WHO". Drug and Alcohol Dependence 17 (2-3): 169–92.

Bustos G, Ferrándiz ML, Sanz MJ, Payá M, Alcaraz MJ. Antinociceptive activity of filenadol on inflammatory pain. Life Sci. 1995;57(14):PL181-6. doi: 10.1016/0024-3205(95)02098-4. PMID: 7564876.

F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 890.

Chin Y Liu, Susan Seen, Gefitinib Therapy for Advanced Non–Small-Cell Lung Cancer, December 2003, Annals of Pharmacotherapy 37(11):1644-53, DOI:10.1345/aph.1D145.

Pao W, Miller V, Zakowski M, et al. (September 2004). "EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib". Proceedings of the National Academy of Sciences of the United States of America 101 (36): 13306–11.

Ogawa N, Haba K, Sora YH, Higashida A, Sato H, Ogawa S (1988). "Comparison of the effects of bifemelane hydrochloride and indeloxazine hydrochloride on scopolamine hydrobromide-induced impairment in radial maze performance". Clinical Therapeutics. 10 (6): 704–11. PMID 3219685.

Ogawa N, Haba K, Yoshikawa H, Ono T, Mizukawa K (August 1988). "Comparison of the effects of bifemelane hydrochloride, idebenone and indeloxazine hydrochloride on ischemia-induced depletion of brain acetylcholine levels in gerbils". Research Communications in Chemical Pathology and Pharmacology. 61 (2): 285–8. PMID 3187197.

Nakamura J, Anraku T, Shirouzu M, Iwashita Y, Nakazawa Y (June 1993). "Effects of indeloxazine HCl on kindled amygdaloid seizures in rats: comparison with the effects of phenytoin, diazepam, ethanol, and imipramine". Pharmacology, Biochemistry, and Behavior. 45 (2): 445–50. doi:10.1016/0091-3057(93)90263-s.

Yamaguchi T, Ohyama M, Suzuki M, et al. (September 1998). "Neurochemical and behavioral characterization of potential antidepressant properties of indeloxazine hydrochloride". Neuropharmacology 37 (9): 1169–76.

Baker JG (February 2005). "The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors". British Journal of Pharmacology. 144 (3): 317–22. doi:10.1038/sj.bjp.0706048.

Ogata J, Okamoto T, Minami K (2003). "Landiolol for the treatment of tachyarrhythmia associated with atrial fibrillation". Can J Anaesth 50 (7): 753.

Paul W. Ament, Pharm.D., Namirah Jamshed, M.D., John P. Horne, M.D., Linezolid: Its Role in the Treatment of Gram-Positive, Drug-Resistant Bacterial Infections, American Family Physician, February 15, 2002 / Volume 65, Number 4.

Swaney SM, Aoki H, Ganoza MC, Shinabarger DL (December 1, 1998). "The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria". Antimicrobial Agents and Chemotherapy 42 (12): 3251–5.

Lemaire A, Buvat J (June 1998). "[Erectile response to intracavernous injection of linsidomine in 38 impotent patients. Comparison with prostaglandin E1]". Progres en Urologie. 8 (3): 388–91.

Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E (1 January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293-317. doi:10.1177/009286150103500134

Kan JP, Mouget-Goniot C, Worms P, Biziere K (1986). "Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat". Biochemical Pharmacology 35 (6): 973–978..

Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C: The role of cytochrome P450 2D6 in the metabolism of moclobemide. Eur Neuropsychopharmacol 1996 Aug;6(3):225-30

Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C: inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacology (Berl). 1998 Jan;135(1):22-6.

Fulton B, Benfield P (September 1996). "Moclobemide. An update of its pharmacological properties and therapeutic use". Drugs 52 (3): 450–74.

https://go.drugbank.com/drugs/DB01618.

Aparasu RR, Jano E, Johnson ML, Chen H (October 2008). "Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients". Am J Geriatr Pharmacother 6 (4): 198–204.

Rosenkranz B, Winkelmann BR, Parnham MJ (May 1996). "Clinical pharmacokinetics of molsidomine". Clinical Pharmacokinetics. 30 (5): 372–84. doi:10.2165/00003088-199630050-00004.

Rosenkranz, B.; Winkelmann, B. R.; Parnham, M. J. (1996). "Clinical pharmacokinetics of molsidomine". Clinical pharmacokinetics 30 (5): 372–384.

https://go.drugbank.com/drugs/DB00680

Ahmmed, G. U.; Hisatome, I.; Kurata, Y.; Makita, N.; Tanaka, Y.; Tanaka, H.; Okamura, T.; Sonoyama, K. et al. (2002). "Analysis of moricizine block of sodium current in isolated guinea-pig atrial myocytes. Atrioventricular difference of moricizine block". Vascular pharmacology 38 (3): 131–141.

https://go.drugbank.com/drugs/DB09285.

Civelli, M.; Vigano, T.; Acerbi, D.; Caruso, P.; Giossi, M.; Bongrani, S.; Folco, G. C. (1991). "Modulation of arachidonic acid metabolism by orally administered morniflumate in man". Agents and actions 33 (3–4): 233–239.

Sheppard, S. (1994). "Moroxydine: The story of a mislaid antiviral". Acta dermato-venereologica. Supplementum 183: 1–9.

Leysen DC (February 1999). "Selective 5-HT2C agonists as potential antidepressants". IDrugs. 2 (2): 109–20.

Sittig, Marshall (1988). Pharmaceutical manufacturing encyclopedia. Park Ridge, N.J., U.S.A: Noyes Publications. p. 1122.

Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–59. doi:10.2174/156802606778249766.

Landau D, Jackson J, Gonzalez G (2008). "A case of demand ischemia from phendimetrazine". Cases J 1 (1): 105.

Maurer HH, Fritz CF (December 1990). "Toxicological detection of pholcodine and its metabolites in urine and hair using radio immunoassay, fluorescence polarisation immunoassay, enzyme immunoassay, and gas chromatography-mass spectrometry". International Journal of Legal Medicine. 104 (1): 43–6. doi:10.1007/BF01816483.

Maurer HH, Fritz CF. Toxicological detection of pholcodine and its metabolites in urine and hair using radio immunoassay, fluorescence polarisation immunoassay, enzyme immunoassay, and gas chromatography-mass spectrometry. Int. J. Legal Med. 104: 43-46, 1990.

Haubrich DR, Ward SJ, Baizman E, Bell MR, Bradford J, Ferrari R, Miller M, Perrone M, Pierson AK, Saelens JK, et al. Pharmacology of pravadoline: a new analgesic agent. J Pharmacol Exp Ther. 1990 Nov;255(2):511-22. PMID: 2243340.

Rothman RB, Katsnelson M, Vu N, et al. (June 2002). "Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain". European Journal of Pharmacology. 447 (1): 51–7.

Zhou F, Ge Z, Chen B. Quizartinib (AC220): a promising option for acute myeloid leukemia. Drug Des Devel Ther. 2019;13:1117-1125, https://doi.org/10.2147/DDDT.S198950.

Chao, Qi; Sprankle, Kelly G.; Grotzfeld, Robert M.; Lai, Andiliy G.; Carter, Todd A.; Velasco, Anne Marie; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; James, Joyce; Zarrinkar, Patrick P.; Patel, Hitesh K.; Bhagwat, Shripad S. (2009). "Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1 b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor". Journal of Medicinal Chemistry 52 (23): 7808–7816.

C. R Ganellin; D. J Triggle; F.. Macdonald (1997). Dictionary of pharmacological agents. CRC Press. p. 1375.

Xu H, Loboz KK, Gross AS, McLachlan AJ (March 2007). "Stereoselective analysis of hydroxybupropion and application to drug interaction studies". Chirality. 19 (3): 163–70. doi:10.1002/chir.20356.

Roth BL, Driscol J. "PDSD Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived from the original on 2013-11-08. Retrieved 2014-03-31.

Fleishaker JC (2000). "Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression". Clinical Pharmacokinetics 39 (6): 413–27.

McCafferty GP, Pullen MA, Wu C, Edwards RM, Allen MJ, Woollard PM, Borthwick AD, Liddle J, Hickey DM, Brooks DP, Westfall TD (2007). "Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 293 (1): R299–305. doi:10.1152/ajpregu.00057.2007.

Borthwick AD, Liddle J (July 2011). "The Design of Orally Bioavailable 2,5-Diketopiperazine Oxytocin Antagonists: From Concept to Clinical Candidate for Premature Labour". Medicinal Research Reviews 31 (4): 576–604.

Chen S, Zhang Q, Wu X, Schultz PG, Ding S (2004) Dedifferentiation of lineage-committed cells by a small molecule. J. Am. Chem. Soc., 126(2):410–411

Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, et al. (September 2005). "Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor". Journal of Medicinal Chemistry. 48 (19): 5900–8. doi:10.1021/jm050101d.

Hunter JM (April 1996). "Rocuronium: the newest aminosteroid neuromuscular blocking drug". British Journal of Anaesthesia. 76 (4): 481–3. doi:10.1093/bja/76.4.481.

Ogura C, Kishimoto A, Kunimoto N, et al. (May 1987). "Clinical pharmacology of a new antidepressant, Y-8894 in healthy young and elderly volunteers". British Journal of Clinical Pharmacology 23 (5): 537–43.

Scoular, I. T.; Monks, Anne; Burgess, C.; Turner, P. (1977). "Human studies on the bioavailability of a quaternary ammonium compound, tiemonium iodide and tiemonium methosulphate". Current Medical Research and Opinion 4 (10): 732–8.

https://drugs.ncats.io/drug/FZ2LZ7U304.

Sambhara D, Aref AA (January 2014). "Glaucoma management: relative value and place in therapy of available drug treatments". Therapeutic Advances in Chronic Disease. 5 (1): 30 43. doi:10.1177/2040622313511286.

Essential of pharmacology,k.d tripathy,6th edn,p-136.

Shpak VM, Shcheglova AIu (August 1968). "[Trioxazine in the treatment of night anxiety in children]" (in Russian). Pediatriia 47 (8): 76–7.

Yu, Chungping; Garcia-Olivares, Jennie; Candler, Shawn; Schwabe, Stefan; Maletic, Vladimir (2020). "New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties". Journal of Experimental Pharmacology. 12: 285–300. doi:10.2147/JEP.S256586.

Case DE, Reeves PR (February 1975). "The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans". Xenobiotica 5 (2): 113–29.

Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. Page 163.

Banerjee M, Ghosh AK, Basak S, Das KD, Gangopadhyay DN. Comparative evaluation of effectivity and safety of topical amorolfine and clotrimazole in the treatment of tinea corporis. Indian J Dermatol. 2011;56(6):657-662. doi:10.4103/0019-5154.91823.

David W. Warnock, Chapter 32 - Antifungal agents, Editor(s): Roger G. Finch, David Greenwood, S. Ragnar Norrby, Richard J. Whitley, Antibiotic and Chemotherapy (Ninth Edition),W.B. Saunders, 2010, Pages 366-382.

Schmidt JL, Blockus LE, Richards RK. The Pharmacology of Pramoxine Hydrochloride: A New Topical Local Anesthetic. Curr Res Anesth Analg. 1953 Nov-Dec;32(6:1):418-25.

Ronald I. Shorr, Angela B. Hoth, Nathan Rawls,Drugs for the Geriatric Patient,W.B. Saunders,2007,Pages 930-1062.

https://go.drugbank.com/drugs/DB09047.

Kocsis B, Domokos J, Szabo D (May 2016). "Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin". Annals of Clinical Microbiology and Antimicrobials. 15 (1): 34.

Georgopapadakou NH, Walsh TJ (February 1996). "Antifungal agents: chemotherapeutic targets and immunologic strategies". Antimicrobial Agents and Chemotherapy. 40 (2): 279–91. doi:10.1128/AAC.40.2.279.

Merck index 2000 edition.

http://www.deadiversion.usdoj.gov/fed_regs/quotas/2013/fr0620.htm.

A. Kerkenaar, Mode of action of tridemorph and related compounds, Editor(s): S. Matsunaka, D.H. Hutson, S.D. Murphy, Mode of Action, Metabolism and Toxicology, Pergamon,1983, Pages 123-127.

Raederstorff D, Rohmer M. The action of the systemic fungicides tridemorph and fenpropimorph on sterol biosynthesis by the soil amoeba Acanthamoeba polyphaga. Eur J Biochem. 1987 Apr 15;164(2):421-6. doi: 10.1111/j.1432-1033.1987.tb11074.x. PMID: 3569273